OTC Daily Alert Stock Watch - Roche Holding Ltd (OTC: RHHBY)
WorldStockWire - Fri Mar 28, 9:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Update on Glaxo's Mekinist-Tafinlar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:30PM CDT
GlaxoSmithKline came out with disappointing news regarding its Tafinlar-Mekinist combination for BRAF V600 E or K mutation-positive unresectable or metastatic melanoma.
Positive Data on Halozyme Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:50PM CDT
Halozyme presented positive top-line data on HTI-501 for the treatment of cellulite.
ThromboGenics Plays Long Game for Eye Disease
Catherine Shaffer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
ThromboGenics NV recently announced that it received a 3 million euro grant from the Flemish agency for Innovation by Science and Technology to support development of new therapeutics for diabetic macular edema. The new program will complement...
ARIAD Candidate in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 5:10PM CDT
ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
Xenon and Genentech Establish New Pain Discovery Collaboration
PR Newswire - Wed Mar 26, 5:00AM CDT
Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain. This new collaboration agreement builds on the strategic alliance established between Xenon and Genentech in 2012 for the discovery and development of compounds and companion diagnostics for the potential treatment of pain.
WPP Acquires Major Stake in Cognifide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 6:00PM CDT
Recently, WPP Digital purchased a majority stake in a UK-based leading digital consultancy, Cognifide, for an undisclosed sum.
Update on Novartis' Xolair and Secukinumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 4:15PM CDT
Novartis (NVS) has a wide range of products and is not dependent on a single product to drive growth. Moreover, the company boasts a robust pipeline.
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Global Generic Drugs Market 2014-2018: Branded Drugs with Sales of Up to US$135 Billion to Go Off-Patent by 2015
M2 - Mon Mar 24, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6q8j7g/global_generic) has announced the addition of the "Global Generic Drugs Market 2014-2018" report to their offering. The analysts forecast the Global Generic Drugs market to grow at a CAGR of 11.02 percent over the period 2013-2018. The patent expiry of top-selling drugs is one of the major drivers contributing to the growth of this market. The market is also witnessing an increase in mergers and acquistions. However, intense competition among vendors could squeeze profit margins, increase pricing pressure, and pose a challenge to the growth of this market. Key vendors dominating this space include Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, and Teva Pharmaceutical Industries Ltd. Other vendors mentioned in the report are 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and Zydus Cadila Healthcare Ltd. Commenting on the report, an analyst from the team said: Mergers and acquisitions has become the core growth strategy among many healthcare vendors; they help vendors grow rapidly and expand their businesses. The Global Generic Drugs market has witnessed a number of mergers and acquisitions among the leading vendors. Vendors have been primarily focusing on mergers and acquisitions to increase their scale, revenue, market share, and competitive advantage. For instance, in November 2012, Actavis acquired Watson Pharmaceuticals and became the third largest generic pharmaceutical company across the globe, with operations in more than 60 countries. In October 2013, Actavis acquired Warner Chilcott plc for approximately US$8.5 billion. Moreover, in 2011, Teva acquired Ratiopharm AG, a leading generic drug manufacturer in Europe, to maintain its position in the market. For more information visit http://www.researchandmarkets.com/research/6q...al_generic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Could Isis Threaten Regeneron and Novartis?
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 22, 10:00AM CDT
Regeneron and Novartis enjoy little competition for their vision-improving drugs Eylea and Lucentis. As a result, sales of Eylea grew to more than $1.8 billion last year, just two years after winning FDA approval in 2011, and sales of Novartis...
FDA Approves Xolair(R) (omalizumab) for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Business Wire - Fri Mar 21, 1:43PM CDT
--Nearly 50 Percent of Patients Have Inadequate Response to H1-antihistamines, Previously the Only Approved Therapy for CIU(3)
A Major Confidence Boost for this Health Care IT Provider
Seth Robey, The Motley Fool - Motley Fool - Thu Mar 20, 5:30PM CDT
Veeva Systems is a provider of cloud-based IT solutions tailored specifically for the life sciences. Their "industry cloud", as they call it, allows customers in the health care space to operate more efficiently by putting everything from customer...
Data on Novartis' Afinitor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 5:05PM CDT
Novartis announced additional results from a phase III trial, BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) on breast cancer drug, Afinitor.
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Specialty Enzymes Market by Source, Type, Application & Geography - Global Trends & Forecasts to 2018
M2 - Thu Mar 20, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpjrtc/specialty_enzymes) has announced the addition of the "Specialty Enzymes Market by Source, Type, Application & Geography - Global Trends & Forecasts to 2018" report to their offering. Specialty enzymes are natural proteins produced from micro organisms, plants and animals. An enzyme serves as catalysts for the chemical process that include the production of pharmaceuticals, diagnostics, research & biotechnology, and biocatalytic solutions. Enzymes increase reaction rates by decreasing the amount of energy required to form a complex of reactants that is competent to produce reaction products. Specialty enzymes according to their type are classified as carbohydrases, proteases, polymerases and nucleases, lipases, and others. Specialty enzymes report covers analysis of the market structure by identifying various sub-segments of the global specialty enzymes market, Revenue forecasts of the global specialty enzymes markets and its various sub-markets/micro-markets with respect to four main regions- North America, Europe, Asia-Pacific, and Rest of the World (RoW). Major trends, drivers, and restraints of the global specialty enzymes market are identified and explained in detail. The specialty enzyme markets include pharmaceutical, research and biotechnology, diagnostics and biocatalysts. Pharmaceutical manufacturers are witnessing increased awareness in incorporating biocatalysis into manufacturing processes. Enzymes are particularly useful to generate isomerically pure pharmaceuticals and fine chemicals In spite of numerous advantages of biocatalysis, manufacturers have been slow to adopt industrial-scale enzymatic approaches. Key Topics Covered: Introduction Executive Summary Premium Insights Market Overview Global Specialty Enzymes Market, By Source Specialty Enzyme Market, By Type Specialty Enzyme Market, By Application Specialty Enzymes Market, By Geography Competitive Landscape Company Profiles List of Tables List of Figures Companies Mentioned - Advanced Enzyme Technology Ltd. - Affymetrix Inc. - Amano Enzyme Inc. - Basf - Bbi Enzymes Ltd. - Codexis Inc. - Life Technologies - Nagase & Co. Ltd. - Roche Holding Ag. - Sanofi S.A. For more information visit http://www.researchandmarkets.com/research/cp...ty_enzymes About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Why Pfizer Investors Should Watch Quark This Summer
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 19, 1:30PM CDT
Pfizer may learn whether it has a potential challenger to Novartis' and Roche's Lucentis and Regeneron and Bayer's Eylea soon. Its development partner, Quark Pharmaceuticals , is expected to complete its phase 2b study of PF-655 in...
Key Takeaways from Inovio Pharmaceuticals, Inc. Earnings Report
George Budwell, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Most developmental stage biotechs eventually face a 'make or break' moment during the course of their life-cycle. Generally speaking, these key events oft-center around clinical trial data that either validate or sink the company's experimental...
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
After Yesterday's Decline of 2.40%, Roche Holding Offers Investors Better Value
Comtex SmarTrend(R) - Fri Mar 14, 4:06PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $36.18 to a high of $36.77. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $36.35 on volume of 5.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.